CONTEXT: The active metabolite of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], is a potent modulator of immune cells in vitro. OBJECTIVE: Our objective was to determine whether the sun-dependent nutrient, cholecalciferol, can alter disease-associated cellular immune abnormalities in patients with multiple sclerosis (MS). DESIGN: This was an open-label, 12-month, randomized controlled trial. SETTING:Patients with MS were recruited from the MS Clinic at St. Michael's Hospital, Toronto. PATIENTS: Forty-nine patients were matched (for age, sex, disease duration, disease-modifying drug, and disability) and enrolled (treated n = 25; control n = 24). Four patients were lost to follow-up (n = 2 from each group). INTERVENTION: Treated patients received increasing doses of cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to a moderate, physiological intake (10,000 IU/d). Control patients did not receive supplements. MAIN OUTCOME MEASURES: At enrollment and at 12 months, peripheral blood mononuclear cell (PBMC) proliferative responses to disease-associated, MS-relevant, and control antigens were measured, along with selected serum biochemical markers. RESULTS: At 12 months, mean serum 25-hydroxyvitamin D [25(OH)D] concentrations were 83 ± 35 nmol/liter and 179 ± 76 nmol/liter in control and treated participants, respectively (paired t, P < 0.001). Serum 1,25(OH)(2)D did not differ between baseline and 1 yr. In treated patients, 12-month PBMC proliferative responses to neuron antigens myelin basic protein and exon-2 were suppressed (P = 0.002). In controls, there were no significant changes in disease-associated PBMC responsiveness. There were no significant differences between groups in levels of selected biomarkers. INTERPRETATION: MS-associated, abnormal T cell reactivities were suppressed in vivo by cholecalciferol at serum 25(OH)D concentrations higher than 100 nmol/liter.
RCT Entities:
CONTEXT: The active metabolite of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], is a potent modulator of immune cells in vitro. OBJECTIVE: Our objective was to determine whether the sun-dependent nutrient, cholecalciferol, can alter disease-associated cellular immune abnormalities in patients with multiple sclerosis (MS). DESIGN: This was an open-label, 12-month, randomized controlled trial. SETTING:Patients with MS were recruited from the MS Clinic at St. Michael's Hospital, Toronto. PATIENTS: Forty-nine patients were matched (for age, sex, disease duration, disease-modifying drug, and disability) and enrolled (treated n = 25; control n = 24). Four patients were lost to follow-up (n = 2 from each group). INTERVENTION: Treated patients received increasing doses of cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to a moderate, physiological intake (10,000 IU/d). Control patients did not receive supplements. MAIN OUTCOME MEASURES: At enrollment and at 12 months, peripheral blood mononuclear cell (PBMC) proliferative responses to disease-associated, MS-relevant, and control antigens were measured, along with selected serum biochemical markers. RESULTS: At 12 months, mean serum 25-hydroxyvitamin D [25(OH)D] concentrations were 83 ± 35 nmol/liter and 179 ± 76 nmol/liter in control and treated participants, respectively (paired t, P < 0.001). Serum 1,25(OH)(2)D did not differ between baseline and 1 yr. In treated patients, 12-month PBMC proliferative responses to neuron antigens myelin basic protein and exon-2 were suppressed (P = 0.002). In controls, there were no significant changes in disease-associated PBMC responsiveness. There were no significant differences between groups in levels of selected biomarkers. INTERPRETATION: MS-associated, abnormal T cell reactivities were suppressed in vivo by cholecalciferol at serum 25(OH)D concentrations higher than 100 nmol/liter.
Authors: D Zehnder; R Bland; M C Williams; R W McNinch; A J Howie; P M Stewart; M Hewison Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: S Winer; I Astsaturov; R Cheung; L Gunaratnam; V Kubiak; M A Cortez; M Moscarello; P W O'Connor; C McKerlie; D J Becker; H M Dosch Journal: J Immunol Date: 2001-02-15 Impact factor: 5.422
Authors: S Winer; I Astsaturov; R K Cheung; K Schrade; L Gunaratnam; D D Wood; M A Moscarello; P O'Connor; C McKerlie; D J Becker; H M Dosch Journal: J Immunol Date: 2001-04-01 Impact factor: 5.422
Authors: Joost Smolders; Evelyn Peelen; Mariëlle Thewissen; Jan Willem Cohen Tervaert; Paul Menheere; Raymond Hupperts; Jan Damoiseaux Journal: PLoS One Date: 2010-12-13 Impact factor: 3.240
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Gauree Gupta Konijeti; Pankaj Arora; Matthew R Boylan; Yanna Song; Shi Huang; Frank Harrell; Christopher Newton-Cheh; Dillon O'Neill; Joshua Korzenik; Thomas J Wang; Andrew T Chan Journal: J Clin Endocrinol Metab Date: 2015-12-14 Impact factor: 5.958
Authors: Elias S Sotirchos; Pavan Bhargava; Christopher Eckstein; Keith Van Haren; Moira Baynes; Achilles Ntranos; Anne Gocke; Lawrence Steinman; Ellen M Mowry; Peter A Calabresi Journal: Neurology Date: 2015-12-30 Impact factor: 9.910
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Leslie M Higuchi; Ying Bao; Joshua R Korzenik; Edward L Giovannucci; James M Richter; Charles S Fuchs; Andrew T Chan Journal: Gastroenterology Date: 2011-12-09 Impact factor: 22.682
Authors: Niyaz Mohammadzadeh Honarvar; Mohammad Hossein Harrirchian; Fariba Koohdani; Fereydoon Siassi; Sima Jafari Rad; Mina Abdolahi; Sama Bitarafan; Eisa Salehi; Mohammad Ali Sahraian; Mohammad Reza Eshraghian; Ali Akbar Saboor-Yarghi Journal: J Mol Neurosci Date: 2013-04-06 Impact factor: 3.444